Ophthalmic Business News

SAN DIEGO — At Eyecelerator@ASCRS here, Peter Menziuso, Johnson & Johnson Vision company group chairman, announced the company will unveil the Elita femtosecond laser at the ASCRS meeting.

Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, are live at the Eyecelerator 2023 with five special guests to discuss the future and developments in eye care.

SAN DIEGO — In this Healio Video Perspective from Eyecelerator@ASCRS, Rob Thornhill discusses the FDA 510(k) clearance of the ZeptoLink IOL positioning system and the benefits the system may provide cataract surgeons.

SAN DIEGO — In this Healio Video Perspective from Eyecelerator@ASCRS, Ben Bergo gives an overview of the positive topline phase 3 results for the Brimochol PF eye drop for the treatment of presbyopia.

SAN DIEGO — The global ophthalmic market was valued at $45.3 billion in 2022, according to Market Scope data presented here.

Brimochol PF, a once-daily eye drop under evaluation for the treatment of presbyopia, achieved primary and secondary endpoints in the pivotal phase 3 BRIO-I clinical trial, according to a press release from Visus Therapeutics.

Centricity Vision received 510(k) clearance from the FDA for the ZeptoLink IOL positioning system, according to a press release.

Intravitreal 4D-150 demonstrated positive interim results for the treatment of wet age-related macular degeneration in a phase 1/2 trial, according to a press release from 4D Molecular Therapeutics.

A single injection of UBX1325 helped patients with diabetic macular edema achieve improved best corrected visual acuity, according to a press release from Unity Biotechnology.

In this episode, I discuss corneal disease and treatments with David Eveleth, PhD, the founder, president and CEO of Trefoil Therapeutics.